bullish
BeiGene (6160 HK): On a Stronger Post-Listing Footing than Ascletis
387 Views13 Aug 2018 03:52
Hong Kong investors have had their first taste of biotech stocks with the recent listings of Ascletis Pharma Inc (1672 HK) and BeiGene Ltd (6160...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Innovent Biologics IPO Valuation: Surprisingly Grounded in Reality15 Oct 2018
- Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene02 Oct 2018
- Hua Medicine IPO Preview: Suffering from the Ascletis Over-Valuation Syndrome03 Sep 2018
- BeiGene (6160 HK): On a Stronger Post-Listing Footing than Ascletis13 Aug 2018
- BeiGene IPO Preview: Lucrative Lifesavers31 Jul 2018
- Ascletis Pharma IPO Preview: Drug-Fuelled Euphoria Needed to Justify Valuation22 Jul 2018
x